On August 25, 2025, Catalyst Pharmaceuticals announced a settlement with Lupin Pharmaceuticals regarding patent litigation but later corrected the misidentified party involved to Inventia Healthcare Ltd., which resolved similar issues concerning the FIRDAPSE® patent.